Retraction: Systematic Treatment Approach to Ventricular Tachycardia in Cardiac Sarcoidosis (Circulation: Arrhythmia and Electrophysiology (2014) 7 (407-413) DOI: 10.1161/CIRCEP.113.000734);Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis

Circulation: Arrhythmia and Electrophysiology

Volumn 7, Issue 3, 2014, Pages 407-413

  Naruse, Yoshihisa ^a   Sekiguchi, Yukio ^a   Nogami, Akihiko ^a   Okada, Hiroyuki ^b   Yamauchi, Yasuteru ^b   MacHino, Takeshi ^a   Kuroki, Kenji ^a   Ito, Yoko ^a   Yamasaki, Hiro ^a   Igarashi, Miyako ^a   Tada, Hiroshi ^a   Nitta, Junichi ^c   Xu, Dongzhu ^a   Sato, Akira ^a   Aonuma, Kazutaka ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c SAITAMA RED CROSS HOSPITAL   (Japan)

Author keywords

Ablation, catheter; Anti arrhythmia agents; Sarcoidosis; Tachycardia, ventricular

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; GALLIUM 67; PROCAINAMIDE; SOTALOL;

ADULT; AGED; ARTICLE; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAINTENANCE DRUG DOSE; MALE; MYOCARDIAL PERFUSION IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PURKINJE FIBER; RECURRENCE RISK; SARCOIDOSIS; SCAR;

ABLATION, CATHETER; ANTI-ARRHYTHMIA AGENTS; SARCOIDOSIS; TACHYCARDIA, VENTRICULAR;

ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHIES; CATHETER ABLATION; COHORT STUDIES; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SARCOIDOSIS; SEX FACTORS; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 84905814742     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/HAE.0000000000000090     Document Type: Erratum

References (20)

1. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111-1118.
2. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92:282-288.
3. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M; Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-1010.
4. Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol. 2004;97:173-182.
5. Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16:140-147.
6. Koplan BA, Soejima K, Baughman K, Epstein LM, Stevenson WG. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm. 2006;3:924-929.
7. Jefc D, Joel B, Good E, Morady F, Rosman H, Knight B, Bogun F. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sar-coidosis: report from a multicenter registry. Heart Rhythm. 2009;6:189-195.
8. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97:2078-2087.
9. Alavi A, Palevsky HI. Gallium-67-citrate scanning in the assessment of disease activity in sarcoidosis. J Nucl Med. 1992;33:751-755.
10. Tsuda T. Statement on the treatment of sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2003;23:105-114.
11. Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol. 2011;34:624-650.
12. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation. 2000;101:1288-1296.
13. Brunckhorst CB, Delacretaz E, Soejima K, Maisel WH, Friedman PL, Stevenson WG. Identifcation of the ventricular tachycardia isthmus after infarction by pace mapping. Circulation. 2004;110:652-659.
14. Xing D, Martins JB. Triggered activity due to delayed afterdepolarizations in sites of focal origin of ischemic ventricular tachycardia. Am J Physiol Heart Circ Physiol. 2004;287:H2078-H2084.
15. Zeppenfeld K, Blom NA, Bootsma M, Schalij MJ. Incessant ventricular tachycardia in fulminant lymphocytic myocarditis: Evidence for origin in the Purkinje system and successful treatment with ablation. Heart Rhythm. 2007;4:88-91.
16. Morishima I, Nogami A, Tsuboi H, Sone T. Verapamil-sensitive left anterior fascicular ventricular tachycardia associated with a healed myocardial infarction: changes in the delayed Purkinje potential during sinus rhythm. J Interv Card Electrophysiol. 2008;22:233-237.
17. Tung R, Josephson ME, Reddy V, Reynolds MR; SMASH-VT Investigators. Infuence of clinical and procedural predictors on ventricular tachycardia ablation outcomes: an analysis from the substrate mapping and ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial (SMASH-VT). J Cardiovasc Electrophysiol. 2010;21:799-803.
18. Mañá J, Gámez C. Molecular imaging in sarcoidosis. Curr Opin Pulm Med. 2011;17:325-331.
19. Matoh F, Satoh H, Shiraki K, Odagiri K, Saitoh T, Urushida T, Katoh H, Takehara Y, Sakahara H, Hayashi H. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol. 2008;51:179-188.
20. Latacha MP, Memon NB, Cuculich PS, Hertel J, Wang Y, Rudy Y, Smith TW. Pathologic examination after epicardial ablation of ventricular tachycardia in cardiac sarcoidosis. Heart Rhythm. 2010;7:705-707.